96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection

MLA

Agarwal, K., et al. 96 Weeks Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Hepatitis B Virus Infection. Jan. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.narcis........ec252ad1e21904b2a46490cf6d07d1e8&authtype=sso&custid=ns315887.

APA

Agarwal, K., Brunetto, M., Seto, W., Lim, Y., Fung, S., Marcellin, P., Ahn, S., Izumi, N., Chuang, W., Bae, H., Sharma, M., Janssen, H., Pan, C., Celen, M., Furusyo, N., Shalimar, Yoon, K., Trinh, H., Flaherty, J., … Chan, H. (Henry L.-Y. (2018). 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.

Chicago

Agarwal, K, M Brunetto, Wk Seto, Ys Lim, S Fung, P Marcellin, Sh Ahn, et al. 2018. “96 Weeks Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Hepatitis B Virus Infection,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.narcis........ec252ad1e21904b2a46490cf6d07d1e8&authtype=sso&custid=ns315887.